Modulating the VIP-VIPR pathway reprograms CAR T cells for superior antitumor efficacy in preclinical cancer models.
Engineered CAR T cells that block an immunosuppressive pathway show stronger tumor-fighting ability and less exhaustion in preclinical models.
VIP (vasoactive intestinal peptide) is an immunosuppressive neuropeptide that suppresses CAR T cell function via the VIPR receptor; engineering CAR T cells to secrete a VIPR antagonist peptide (CAR/VIPRa) kept them metabolically quiescent during manufacturing yet enabled strong bioenergetic response after antigen stimulation. In multiple preclinical cancer models CAR/VIPRa T cells showed greater tumor infiltration, reduced exhaustion, and superior antitumor efficacy compared to standard CAR T cells.
What the study was
- Study design
- preclinical experimental
- Population
- preclinical cancer models (syngeneic and xenogeneic mouse, human cells in vitro)
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Science Translational Medicine
Why it surfaced
Novel armored CAR-T strategy targeting the immunosuppressive VIP-VIPR neuropeptide axis addresses two fundamental CAR-T limitations (poor product phenotype and lack of endogenous immune engagement) simultaneously; multiple cancer model validation in a top journal warrants pipeline monitoring.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.